Warning letter
Morton Grove Pharmaceuticals Inc.: warning letter of May 25, 1999
FDA warning letter UCM067372 · Chicago District Office
Key facts
| Reference number | UCM067372 |
|---|---|
| Company | Morton Grove Pharmaceuticals Inc. |
| Subject | Good Manufacturing Practices Deviations |
| Issue date | May 25, 1999 |
| Posted date | May 25, 1999 |
| Issuing office | Chicago District Office |
| Product type | Drugs |
| CFR sections cited | 21, 211, 211.22, 211.67, 211.100, 211.113, 211.165, 211.188, 211.192, 211.22(d), 211.100(b), 211.165(d) |
| Country | 3 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: